Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Dyslipidemia, Obesity and Metabolic Dysfunction-Associated Fatty Liver Disease: From Roots...
share announcement

Dyslipidemia, Obesity and Metabolic Dysfunction-Associated Fatty Liver Disease: From Roots to Management

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Endocrinology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2511

Special Issue Editors

Dr. Andrej Belančić

E-Mail Website
Guest Editor
1. Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Krešimirova 42, 51000 Rijeka, Croatia
2. Department of Basic and Clinical Pharmacology with Toxicology, Faculty of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia
Interests: clinical pharmacology; diabetes; evidence-based medicine; metabolic syndrome; obesity
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Željko Krznarić

E-Mail Website
Guest Editor
Department of Gastroenterology, Hepatology and Nutrition, Clinical Hospital Centre & School of Medicine Zagreb, Zagreb, Croatia
Interests: gastroenterology; hepatology; metabolic dysfunction-associated fatty liver disease; nutrition

Special Issue Information

Dear Colleagues,

Patients with metabolic dysfunction-associated fatty liver disease (MAFLD), often considered the hepatic manifestation of metabolic syndrome (MetS), represent a population frequently suffering from atherogenic dyslipidemia and posing a significantly increased cardiovascular risk. Since dyslipidemia, obesity/MetS and MAFLD share etiopathogenesis roots and are all major drivers of atherosclerotic cardiovascular disease, impaired quality of life and reduced life span, their early detection and comprehensive multidisciplinary management are warranted.

Considering their constantly growing prevalence and associated global public health concerns, we are collating this Special Issue titled “Dyslipidemia, Obesity and Metabolic Dysfunction-Associated Fatty Liver Disease: From Roots to Management”.

For this Special Issue, we aim to publish outstanding contributions in the key fields covered by the journal, which will make a great contribution to the community. Thus, we believe that Medicina is an excellent platform to support such an overview on the current evidence and insights regarding dyslipidemia, obesity/metabolic syndrome and MAFLD.

We hope that our Special Issue will draw the attention of the readers, scientists and clinicians in general.

Dr. Andrej Belančić
Prof. Dr. Željko Krznarić
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adipose tissue
  • dyslipidemia
  • metabolic dysfunction-associated fatty liver disease
  • metabolic syndrome
  • obesity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1751 KiB  
Article
The Trend of Changes in Adiponectin, Resistin, and Adiponectin–Resistin Index Values in Type 2 Diabetic Patients with the Development of Metabolic Syndrome
by Almir Fajkić, Rijad Jahić, Malik Ejubović, Miralem Đešević, Amira Jagodić Ejubović and Orhan Lepara
Medicina 2024, 60(11), 1795; https://doi.org/10.3390/medicina60111795 - 1 Nov 2024
Viewed by 992
Abstract
Background and Objectives: This study aimed to investigate the novel adiponectin–resistin (AR) index as a predictor of the development of metabolic syndrome (MetS) in individuals with type 2 diabetes mellitus (T2DM). MetS is common in T2DM and increases cardiovascular risk. Adiponectin and [...] Read more.
Background and Objectives: This study aimed to investigate the novel adiponectin–resistin (AR) index as a predictor of the development of metabolic syndrome (MetS) in individuals with type 2 diabetes mellitus (T2DM). MetS is common in T2DM and increases cardiovascular risk. Adiponectin and resistin, adipokines with opposing effects on insulin sensitivity and inflammation, make the AR index a potential marker for metabolic risk. Materials and Methods: This prospective observational study included 80 T2DM participants (ages 30–60) from Sarajevo, Bosnia and Herzegovina, over 24 months. The participants were divided into two groups: T2DM with MetS (n = 48) and T2DM without MetS (n = 32). Anthropometric data, biochemical analyses, and serum levels of adiponectin and resistin were measured at baseline and every six months. The AR index was calculated using the formula AR = 1 + log10(R) − 1 + log10(A), where R and A represent resistin and adiponectin concentrations. Logistic regression identified predictors of MetS. Results: T2DM patients who developed MetS showed a significant decline in adiponectin levels (40.19 to 32.49 ng/mL, p = 0.02) and a rise in resistin levels (284.50 to 315.21 pg/mL, p = 0.001). The AR index increased from 2.85 to 2.98 (p = 0.001). The AR index and resistin were independent predictors of MetS after 18 months, with the AR index showing a stronger predictive value (p = 0.007; EXP(B) = 1.265). Conclusions: The AR index is a practical marker for predicting MetS development in T2DM participants, improving metabolic risk stratification. Incorporating it into clinical assessments may enhance early detection and treatment strategies. Full article
(This article belongs to the Special Issue Dyslipidemia, Obesity and Metabolic Dysfunction-Associated Fatty Liver Disease: From Roots to Management)
►▼ Show Figures

Figure 1

17 pages, 3113 KiB  
Article
Beyond Blood Sugar: Low Awareness of Kidney Disease among Type 2 Diabetes Mellitus Patients in Dalmatia—Insights from the First Open Public Call
by Josipa Radić, Marijana Vučković, Hana Đogaš, Marina Grubić, Andrej Belančić, Leida Tandara, Lucija Šolić Šegvić, Ivana Novak and Mislav Radić
Medicina 2024, 60(10), 1643; https://doi.org/10.3390/medicina60101643 - 8 Oct 2024
Viewed by 1106
Abstract
Background and Objectives: Kidney disease (KD) is a common complication of diabetes mellitus (DM) associated with adverse outcomes of renal failure, cardiovascular disease, and mortality. The aim of this study was to determine the prevalence and awareness of the KD among the [...] Read more.
Background and Objectives: Kidney disease (KD) is a common complication of diabetes mellitus (DM) associated with adverse outcomes of renal failure, cardiovascular disease, and mortality. The aim of this study was to determine the prevalence and awareness of the KD among the DM type 2 (T2DM) patients. Materials and Methods: This cross-sectional study was conducted at the University Hospital of Split between November and December of 2023 during an open call for DM patients. For each participant, blood and urine samples, along with relevant medical information, were collected, and adherence to the Mediterranean diet (MeDi) was assessed using the Mediterranean Diet Service Score (MDSS). Furthermore, blood pressure was measured, along with body composition and anthropometric parameters. Results: Of 252 T2DM patients with a median age of 67 years (IQR: 60–73), 130 (51.6%) were women. The median duration of T2DM was 10 years (IQR: 6–20). Despite the fact that 80.95% of total participants reported receiving dietary guidelines from any source, only 53.2% reported adhering to the suggested instructions, while according to the MDSS, only 7.2% adhered to the MeDi. The median body mass index was 27.6 kg/m2 (24.2–31), with 70.1% of participants overweight or obese. Only 6% of participants believed they had KD, but after blood and urine sample analysis, 31% were found to have KD. Conclusions: This study highlights a significant gap in awareness of KD, low adherence to MeDi, and a high prevalence of obesity among T2DM patients. Due to the increasing number of T2DM patients, it is crucial to improve healthy lifestyle education and make modifications within this group, as well as perform regular screening for KD and medical check-ups. Full article
(This article belongs to the Special Issue Dyslipidemia, Obesity and Metabolic Dysfunction-Associated Fatty Liver Disease: From Roots to Management)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop